Med Spa EBITDA Benchmarks: What Well-Run Practices Actually Look Like

A well-run single-location medical spa targets 27-38% EBITDA at $1-1.5 million in annual revenue, according to Growth99 and Zenoti benchmark data. Most practices run 10 to 15 points below this because labor, injectable COGS, device leases, and owner compensation are never reconciled against revenue on a consistent schedule.

The EBITDA question for a med spa has a specific answer, and it comes from industry data, not general small-business benchmarks. A consultant with no aesthetics background will give you a range built for retail or professional services. The number you need comes from practices at the same revenue level, with the same revenue mix, running the same ownership structure.

Growth99's 2026 State of Aesthetic and Elective Wellness Marketing Report places average profit margins at 38% for well-run practices, with average annual revenue of $1.39 million. Zenoti's 2025 Beauty and Wellness Benchmark Report, published March 2026, shows average med spa annual revenue of $1,035,229, with the top 25% of practices averaging $1,776,829 and the top 10% reaching $3,219,354.

The market itself is expanding at a 12.48% compound annual growth rate through 2030, per Mordor Intelligence (April 2026). That growth rate does not translate into margin automatically. The gap between average and top-performing practices has specific causes, and a correctly structured P&L makes each one visible.

What Is EBITDA and Why Does It Matter for a Med Spa?

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It measures operating profitability before the effects of how the business is financed, how equipment is expensed, and what tax structure the owner uses. For a medical spa, EBITDA is the most useful profitability metric for three specific purposes.

First, it allows meaningful comparison against industry benchmarks. A practice that purchased its laser outright shows a large depreciation charge that reduces net income. A practice that leases the same device shows a monthly lease payment as an operating expense. EBITDA normalizes both to the same operating result, making peer comparison valid.

Second, it is what buyers and private equity groups use to value the business. Med spa acquisition multiples are typically expressed as a multiple of EBITDA or adjusted EBITDA. A practice selling at 5x EBITDA with $400,000 in EBITDA is valued at $2 million.

A practice with the same revenue but $250,000 in EBITDA sells for $1.25 million. The difference is not the revenue line. It is the four cost categories that drive EBITDA compression.

Third, it is the metric that reveals whether growth is actually working. Revenue growing at 20% while EBITDA stays flat means expenses are growing faster than revenue. EBITDA growth confirms that scale is producing leverage, not just more activity.

38%
Average profit margin benchmark for well-run med spas (Growth99, 2026 State of Aesthetic and Elective Wellness Marketing Report)
Average annual revenue benchmark: $1.39 million. Most practices running at this revenue level report actual margins 10-15 points below this without a structured weekly P&L.

What Is a Good EBITDA Margin for a Medical Spa?

Using data from Growth99 and Zenoti, three distinct performance tiers emerge for single-location medical spas. The table below shows the revenue levels, EBITDA targets, and key cost ratios associated with each tier. These ranges represent directional targets based on benchmark data. Individual practice results vary based on market, revenue mix, and ownership structure.

Revenue Tier Avg Annual Revenue Target EBITDA % Labor % of Revenue Injectable COGS %
Average $1,035,229 20–27% 42–48% 35–42%
High Achiever (top 25%) $1,776,829 27–32% 38–42% 32–38%
Top Earner (top 10%) $3,219,354 32–38% 35–40% 30–35%

Sources: Zenoti, 2025 Beauty and Wellness Benchmark Report (March 2026); Growth99, 2026 State of Aesthetic and Elective Wellness Marketing Report. EBITDA percentage ranges and cost ratios are directional targets based on benchmark data.

The revenue jump between average and top-earner tiers is not purely a function of adding patients. Top earners run at 78% staff utilization versus 47% for the average practice, per Zenoti.

They also report a 69% rebooking rate within 24 hours of a completed appointment, compared to 40% for the average. Higher throughput on the same fixed cost base is the mechanical source of EBITDA leverage at scale.

What Is the Average Revenue for a Medical Spa?

Zenoti reports average med spa annual revenue of $1,035,229, with the high achiever group (top 25%) averaging $1,776,829.

Growth99 places the average at $1.39 million, which likely reflects a sample weighted toward more established practices. Both sources confirm that the market bifurcates sharply: 65% of practices expect revenue growth in 2026 (Growth99), but the top decile grows at a rate that compounds the distance between tiers.

The repeat patient rate benchmark from Growth99 is 73%, meaning nearly three-quarters of revenue at the average practice comes from returning patients.

This matters for EBITDA because patient acquisition cost is one of the largest variable marketing expenses. Practices with high repeat rates need to spend less per dollar of revenue on new patient marketing, which frees margin for EBITDA rather than acquisition.

$3.2M
Average annual revenue for top earner practices (top 10%). Zenoti, 2025 Beauty and Wellness Benchmark Report.
Average practice: $1,035,229. High achiever (top 25%): $1,776,829. The top earner gap is a utilization and rebooking story, not just a pricing story.

Which Four Line Items Drive the Gap Between Average and Top-Performing Practices?

Four specific cost categories account for most of the EBITDA gap between the average and top-performing med spa. Each one is measurable from a correctly structured QuickBooks P&L. None of them is visible when the chart of accounts uses the default setup.

1. Labor Percentage

Labor is the largest controllable expense at most practices and the first place compression happens when revenue does not scale with headcount. Top earners run labor at 35 to 40% of revenue. Average practices run 42 to 48%. Each percentage point above the benchmark reduces EBITDA by one point at any revenue level.

The BLS reports a nurse practitioner mean annual wage of $132,050 (Occupational Employment and Wage Statistics, May 2024). A single NP at $132,050 in annual compensation represents 12.7% of revenue at the average $1.04 million practice. At the top earner level ($3.2 million), the same salary is 4.1% of revenue.

Scale produces labor leverage. Below a certain revenue threshold, clinical labor runs structurally above benchmark and the owner cannot fix it by cutting hours. The only real fix is growing revenue per clinical hour.

Estheticians run at a different cost point. BLS reports esthetician mean hourly earnings of $19.98 (May 2024). The leverage concern for esthetician labor is throughput: how many billable appointments per shift, at what average ticket, against an hourly cost near $20. Practices that run esthetic services at below-target utilization accumulate labor cost without corresponding revenue.

2. Injectable COGS

Injectable product cost runs 30 to 42% of injectable service revenue at most practices, depending on vendor tier and pricing discipline. For a practice where injectables represent 50% of total revenue, injectable COGS at 38% of injectable revenue reduces the gross margin on half the P&L by more than one-third before any operating expenses are applied.

The EBITDA impact of injectable COGS is compounded by a common accounting error: Allergan, Galderma, and Merz invoices coded to Medical Supplies (an operating expense) rather than to a COGS account.

When this happens, the gross margin appears healthy because product cost is invisible above the operating expense line. EBITDA then looks inflated relative to peers, until the books are correctly structured and COGS moves above the gross profit line where it belongs.

Most EBITDA improvement at a med spa does not come from adding revenue. It comes from seeing the real cost structure for the first time. Labor above 42%, injectable COGS in the wrong account, and device leases buried in rent have been compressing margin for months before anyone runs the number.

3. Device Lease Payments

Device lease payments represent a fixed cost against variable utilization. A practice with three devices and monthly leases totaling $12,000 carries $144,000 in annual fixed device cost regardless of how many treatments those devices complete. At 47% average utilization, two of those three devices are likely running below break-even in any given month.

The EBITDA impact is direct and predictable: each dollar of device lease cost that is not matched by net device treatment revenue reduces EBITDA by one dollar.

The problem is invisible when device leases are coded to the same Rent Expense account as real estate. The fix is a separate Device Lease account, device-level revenue tracking from the booking system, and a weekly break-even review for each device.

4. Owner Compensation Normalization

Owner compensation above the market rate for the owner's clinical or managerial role inflates the expense base and compresses reported EBITDA. An owner injector paying themselves $300,000 annually in a market where an NP injector earns $132,050 (BLS, May 2024) is running $167,950 in above-market compensation through the P&L.

That amount depresses EBITDA on the books. An acquirer or investor normalizes it back out when calculating adjusted EBITDA.

The practical implication for an owner who is not planning to sell is that the P&L looks worse than the business actually performs at market compensation. For an owner planning a future transaction, normalizing compensation before due diligence removes a significant apparent discount from the valuation.

How Do You Calculate Med Spa EBITDA from a QuickBooks P&L?

The calculation starts with net income from the QuickBooks P&L, then adds back four categories of charges.

Step 1: Pull net income from the QuickBooks P&L for the period.

Step 2: Add back interest expense. Any interest paid on practice loans, SBA financing, or equipment financing is added back to remove the effect of capital structure from operating profit.

Step 3: Add back income taxes. Taxes paid at the entity level (for C-corps) or estimated taxes tracked through the books are added back.

Step 4: Add back depreciation and amortization. Depreciation on purchased equipment and amortization of startup or acquisition costs are non-cash charges that reduce net income without reducing cash. Both are added back.

Step 5 (for adjusted EBITDA): Normalize owner compensation. Subtract market-rate compensation for the owner's role and add back the amount above market. This produces adjusted EBITDA, which is the number comparable to industry benchmarks and what acquirers use for valuation.

If the QuickBooks chart of accounts is set up correctly, with injectable COGS in the right account, device leases in a separate expense line, and deferred revenue as a liability rather than income, this calculation is a five-minute pull from a QuickBooks report. With the default account structure, it requires a manual reconciliation that most owners never complete.

Your real EBITDA in the first weekly report.

Spa Ledger builds the account structure, weekly P&L, and EBITDA calculation for your practice from day one. Most clients see their real margin, with injectable COGS, device leases, and owner comp normalized, within the first week. First month is free.

Reserve Your First Month

Frequently asked questions

A well-run single-location medical spa targets 27 to 38% EBITDA at $1 to 1.5 million in annual revenue. High achievers in the top 25% of practices typically run 27 to 32% EBITDA. Top earners in the top 10% approach 32 to 38%. The average practice running at $1.04 million typically achieves 20 to 27% EBITDA. Practices below 18% EBITDA usually have a structural cost problem, not just a revenue problem: labor, injectable COGS, or device leases running above benchmark.
Start with net income from the QuickBooks P&L. Add back interest expense on any practice loans or equipment financing, income taxes paid at the entity level, depreciation on purchased equipment, and amortization of startup or acquisition costs. For adjusted EBITDA (the number comparable to industry benchmarks), also normalize owner compensation by adding back any amount above market rate for the owner's clinical or managerial role. The result is adjusted EBITDA, which is what buyers and lenders use.
Growth99's 2026 benchmark places average profit margins at 38% for well-run practices at an average annual revenue of $1.39 million. Zenoti's 2025 data shows average annual revenue of $1,035,229 across the broader benchmark set. Most practices operating near the average revenue level report actual net margins of 15 to 25% before owner compensation normalization. That is lower than the headline 38% benchmark, which reflects well-run practices rather than the full market average.
Four line items account for most of the gap: labor running above 42% of revenue, injectable COGS coded to operating expenses instead of COGS (which understates gross margin), device lease payments mixed with real estate rent (which hides per-device fixed costs), and owner compensation above market rate (which inflates the expense base). Correcting the QuickBooks account structure and reviewing these four categories against benchmarks typically reveals the source of margin compression within the first weekly P&L cycle.
Injectable COGS runs 30 to 42% of injectable service revenue depending on vendor tier and pricing discipline. At a practice where injectables represent 50% of total revenue, a 38% injectable COGS rate reduces gross margin on half the P&L before any operating expenses. The accounting error that compounds this is coding Allergan and Galderma invoices to Medical Supplies rather than a COGS account, which makes injectable gross margin invisible and inflates apparent EBITDA until the error is corrected.